Safety of modern oral contraception: the options for women: Lessons to be learned

被引:6
作者
Benagiano, G [1 ]
Primiero, FM [1 ]
机构
[1] Ist Super Sanita, I-00161 Rome, Italy
关键词
myocardial infarction; oral contraceptives; pill scare; safety of medicines; venous thromboembolism;
D O I
10.1093/humupd/5.6.633
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The relatively short history of hormonal contraception has been marked by a series of 'pill scares', all of which-after creating panic among users-were proven to be unfounded in terms of public health impact, The latest pill scare, provoked by regulatory action in the United Kingdom and the Federal Republic of Germany in response to the publication of a series of articles indicating a doubling of risk of deep venous thrombosis in users of oral contraceptives containing third-generation progestins, seems finally settled: both the British and the German Drug Regulatory Authorities have now reverted their verdict. The damage unfortunately stays: hundreds of thousands of women have been compelled to abandon the pill of their choice, often deciding to drop contraception altogether, thereby exposing themselves to unwanted pregnancy and-in a number of cases-to pregnancy termination, This latest episode should be turned into something positive: we need to learn that, in the case of drugs in widespread use, before restrictive action is taken-and except for very rare and specific instances-the scientific community must carry out an exhaustive debate on the reality and importance of the observed effects. Although the public should, in each instance, be properly informed, it is only after this process has been completed that restrictive action should be taken, It is hoped that, after this last episode, all concerned have learned this simple principle and will accept being guided by it from now on.
引用
收藏
页码:633 / 638
页数:6
相关论文
共 20 条
  • [1] ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN
    BLOEMENKAMP, KWM
    ROSENDAAL, FR
    HELMERHORST, FM
    BULLER, HR
    VANDENBROUCKE, JP
    [J]. LANCET, 1995, 346 (8990): : 1593 - 1596
  • [2] Committee on the Safety of Medicines, 1995, COMB OR CONTR THROMB
  • [3] Balancing risks and benefits of oral contraception
    Edwards, RG
    Beard, HK
    Bradshaw, JP
    [J]. HUMAN REPRODUCTION, 1997, 12 (11) : 2339 - 2340
  • [4] FARLEY TMM, 1995, LANCET, V346, P1582
  • [5] Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives
    Farmer, RDT
    Newson, RB
    MacRae, K
    Lawrenson, RA
    Tyrer, F
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1997, 51 (06) : 630 - 635
  • [6] Population-based study of risk of venous thromboembolism associated with various oral contraceptives
    Farmer, RDT
    Lawrenson, RA
    Thompson, CR
    Kennedy, JG
    Hambleton, IR
    [J]. LANCET, 1997, 349 (9045) : 83 - 88
  • [7] RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS
    JICK, H
    JICK, SS
    GUREWICH, V
    MYERS, MW
    VASILAKIS, C
    [J]. LANCET, 1995, 346 (8990): : 1589 - 1593
  • [8] The differential risk of oral contraceptives:: the impact of full exposure history
    Lewis, MA
    MacRae, KD
    Kühl-Habich, D
    Bruppacher, R
    Heinemann, LAJ
    Spitzer, WO
    [J]. HUMAN REPRODUCTION, 1999, 14 (06) : 1493 - 1499
  • [9] The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
    Lewis, MA
    Heinemann, LAJ
    MacRae, KD
    Bruppacher, R
    Spitzer, WO
    [J]. CONTRACEPTION, 1996, 54 (01) : 5 - 13
  • [10] Lidegaard O, 1997, LANCET, V349, P1621, DOI 10.1016/S0140-6736(97)26022-8